Before injecting, always check that the medication looks clear and normal
CL Answer What are the side effects of magnesium supplements
Despite her efforts, the scale wouldnt budge
1-2 servings daily, depending on activity level and climate Increase on hot days, during exercise, or if eating very little Monitor urine colorpale yellow indicates good hydration Managing Active Nausea When nausea is severe: Dilute electrolytes more than usual (1 stick in 24-32 oz water) Serve ice-cold for easier consumption Take small sips every 5-10 minutes rather than drinking full glasses Avoid citrus flavors if they worsen nauseaunflavored or mild flavors work best GLP-1 Hydration Protocol: Complete Daily Schedule Upon waking: 8-12 oz electrolyte drink (prevents morning nausea, rehydrates after overnight fast) Mid-morning: 8-12 oz plain water Before lunch: Finish first electrolyte serving if not yet complete Afternoon (2-4 PM): Second electrolyte serving if experiencing fatigue or eating very little Between meals: Plain water as tolerated Evening: Avoid large fluid volumes within 2 hours of bed (GLP-1s slow digestion, which can worsen nighttime reflux) Total daily intake goal: 64-80 oz total fluids, with 32-40 oz from electrolyte solutions Can You Drink Too Many Electrolytes on GLP-1s
Funding: GSK (212620) Disclosures: Gideon Hirschfield: Intercept: Consultant, GSK: Consultant, CymaBay: Consultant, Ipsen: Consultant, Falk: Consultant, Pliant: Consultant, Morphogen: Consultant, Roche: Consultant, Mirum: Consultant, Advanz: Consultant, Chemomab: Consultant, Gilead: Consultant, Kowa: Consultant, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support, David Jones: Nothing to Disclose, Andreas Kremer: Abbvie: Advisor, Advanz: Advisor, Alentis: Advisor, AlphaSigma: Speaking and Teaching, AstraZeneca: Advisor, Avior: Advisor, Bayer: Advisor, CymaBay: Advisor, Escient: Advisor, Falk: Speaker, Falk: Speaker, Gilead: Advisor, GSK: Advisor, Intercept: Advisor, Ipsen: Speaking and Teaching, Ipsen: Speaking and Teaching, Mirum: Advisor, Mirum: Advisor, MSD: Advisor, Myr: Advisor, Roche: Advisor, Takeda: Advisor, Viofor: Advisor, Marlyn Mayo: CymaBay: Grant/Research Support, CymaBay: Consultant, GSK: Grant/Research Support, GSK: Consultant, Intercept: Grant/Research Support, IntraSana: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mallinckrodt: Grant/Research Support, Mallinckrodt: Consultant, Mirum: Grant/Research Support, Target RWE: Grant/Research Support, Atsushi Tanaka: Nothing to Disclose, Pietro Andreone: Nothing to Disclose, Jidong Jia: Nothing to Disclose, Qinglong Jin: Nothing to Disclose, Ricardo Macas-Rodrguez: Nothing to Disclose, Alexander Cobitz: Nothing to Disclose, Brooke Currie: GSK: Employee, GSK: Stock - publicly traded company, Ciara Gorey: Nothing to Disclose, Eunhye Kang: Nothing to Disclose, Ivana Lazic: GSK: Employee, Danielle Podmore: Nothing to Disclose, Andrea Ribeiro: Nothing to Disclose, Jennifer Shannon: Nothing to Disclose, Brandon Swift: GSK: Employee, Philip Troke: Nothing to Disclose, Megan McLaughlin: Nothing to Disclose, Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant 2362 PERIDUCTAL IRON-CORRECTED T 1 IS A PREDICTOR OF ADVERSE OUTCOMES IN LARGE-DUCT PRIMARY SCLEROSING CHOLANGITIS Emmanuel Selvaraj 1 Bruno Paun 2 Cayden Beyer 2 Amy Herlihy 2 Michael Brady 2 Emma Culver 1 Adam Bailey 1 Michael Pavlides 3 , 1 University of Oxford, 2 Perspectum Ltd, 3 Oxford University Background: Concentric periductal fibrosis, commonly referred to as onion skin fibrosis, is a histological hallmark of primary sclerosing cholangitis (PSC)
